Granted Patent B2

US 12,496,315 · App. 16/730,603 · Granted Dec 16, 2025

Inventors: Jonathan N. Thon (Cambridge, MA); Brad Dykstra (Cambridge, MA); Brenden William Smith (Cambridge, MA); Christian Gerald Peters (Cambridge, MA); Thomas Carl Schulz (Cambridge, MA)

Assignee: Stellular Bio, Inc.

A61K35/19A61K9/127A61K9/1271A61K47/6901C12N5/0607C12N5/0644C12N5/0696C12N2501/115C12N2501/125C12N2501/145C12N2501/155C12N2501/165C12N2501/2303C12N2501/2306C12N2501/26C12N2501/415C12N2501/91C12N2506/03C12N2506/45C12N2513/00C12N2533/52

Abstract

Claims (22)

1 . A method of producing modified megakaryocyte progenitors (preMKs) expressing a transgene comprising:

(i) genetically engineering iPSCs to express a transgene for producing a therapeutic agent, wherein the therapeutic agent comprises at least one of a chemokine, a cytokine, a growth factor, a polypeptide, anti-angiogenic agent, a polynucleotide, or a small molecule;

(ii) self-aggregating of the iPSCs in step (i) in matrix-independent culture to form spheroids comprising iPSCs using continuous shaking or stirring such that the spheroids comprising iPSCs are in a suspended state;

(iii) maintaining, during the self-aggregating of the iPSCs into the spheroids, pluripotency of the iPSCs in the spheroids in the matrix-independent culture in a presence of FGF2 in an amount sufficient to maintain pluripotency of the iPSCs;

(iv) directing differentiating of at least a portion of the iPSCs in the spheroids in a first differentiation culture condition to generate hemogenic endothelial (HE) cells for a first time period, the first differentiation culture condition comprising BMP4 and VEGF in an amount sufficient to direct the differentiating of the iPSCs to the HE cells;

(v) directing differentiating of the HE cells in the spheroids in a second differentiation culture condition to generate preMKs expressing the transgene for a second time period, the second differentiation culture condition comprising IL-6, IL-3, TPO, FLT3-L, and SCF in an amount sufficient to direct the differentiating of the HE cells to the preMKs; and

(vi) maintaining the spheroids from step (v), wherein the spheroids continuously produce and release from the maintained spheroids additional preMKs expressing the transgene.

2 . The method of claim 1 , wherein greater than 50% of the preMKs express CD41+.

3 . The method of claim 1 , wherein greater than 50% of the preMKs express CD43+.

4 . The method of claim 1 , wherein greater than 50% of the preMKs are CD14−.

5 . The method of claim 1 , wherein the preMKs have altered cell signaling compared to a donor derived preMKs.

6 . The method of claim 1 , wherein the pre-MKs express a receptor.

7 . The method of claim 1 , wherein step (iv) further comprises continuously harvesting and differentiating the preMKs released from the spheroids under ultra-low-adherent static conditions.

8 . The method of claim 1 , wherein step (iv) further comprises continuously harvesting preMKs released from the spheroids and at least one of (a) culturing the preMKs to form megakaryocytes separately and (b) pooling preMKs released over time for storage.

9 . The method of claim 1 , wherein the self-aggregating comprises low-adherent or non-adherent conditions.

10 . The method of claim 1 , wherein the self-aggregating is performed in a vessel comprising hydrophilic or neutrally charged surfaces.

11 . A method of producing modified megakaryocyte progenitors (preMKs) expressing a transgene comprising:

(i) genetically engineering iPSCs to express a transgene for producing a therapeutic agent, wherein the therapeutic agent comprises at least one of a chemokine, a cytokine, a growth factor, a polypeptide, anti-angiogenic agent, a polynucleotide, or a small molecule;

(ii) self-aggregating of the iPSCs in step (i) in matrix-independent culture to form spheroids comprising iPSCs using continuous shaking or stirring such that the spheroids comprising iPSCs are in a suspended state;

(iii) maintaining, during the self-aggregating of the iPSCs into the spheroids, the iPSCs in the spheroids in the matrix-independent culture in a presence of FGF2 in an amount sufficient to maintain pluripotency of the iPSCs;

(iv) directing differentiating of at least a portion of the iPSCs in the spheroids in a feeder cell-free first differentiation culture condition to generate hemogenic endothelial (HE) cells for a first time period, the first differentiation culture condition being matrix independent and comprising BMP4 and VEGF in an amount sufficient to direct the differentiating of the iPSCs to the HE cells; and

directing differentiating of the HE cells in the spheroids in a feeder cell-free second differentiation culture condition to generate preMKs expressing the transgene for a second time period, the second differentiation culture condition being matrix independent and comprising one or more of FGF2, IL-6, IL-3, TPO, FLT3-L, or SCF in an amount sufficient to direct the differentiating of the HE cells to the preMKs.

Assignments (2)

Continuity (3)

References Cited (224)